Нитроглицерин

Quick links to important sections

Нитроглицерин

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Нитроглицерин

What is Nitroglycerin? (Нитроглицерин)

Property Description
Active ingredient Glyceryl Trinitrate (Nitroglycerin)
Form Sublingual tablets, Oral spray, Injection solution
Pharmacological class Organic Nitrate / Vasodilator
General use Rapidly reducing cardiac workload
Origin Synthetic

What is Nitroglycerin and What Class Does It Belong To?

Nitroglycerin is a medication primarily used for heart conditions, and its full chemical name is glyceryl trinitrate. It is classified as an organic nitrate and a vasodilator, belonging to the essential cardiovascular agents group. This synthetic compound is widely recognized for its clinical effectiveness in emergency settings.

Nitroglycerin is the International Nonproprietary Name (INN), meaning it is the generic, standard identifier for the active substance. The drug works by serving as a source of nitric oxide, which causes smooth muscle relaxation. This mechanism is the key to why the medicine quickly widens constricted vessels.


Forms of Release and Composition: Single or Combination Drug?

Nitroglycerin is typically a single-ingredient product (monopreparat), containing only glyceryl trinitrate as the active compound. It is not usually combined with other therapeutic substances for its immediate-release forms. It is available in various dosage forms, most commonly as sublingual tablets (designed to dissolve under the tongue), oral spray, or solution for injection.

The formulation consists of the active ingredient combined with suitable inert bases or vehicles to ensure stability and proper route of administration. The variety of forms ensures the drug can be administered for different speeds of onset, from emergency rapid action to continuous support.


What is the General Purpose of Nitroglycerin Use?

The general purpose of Nitroglycerin is to rapidly reduce the workload on the heart and increase the supply of oxygen-rich blood to the heart muscle. This medication is critically important for rapid relief when symptoms of oxygen deprivation occur.

It achieves this through its main function as a powerful vasodilator, causing blood vessel walls to relax. The primary therapeutic use of the active substance is related to relaxation of vascular smooth muscle. By widening the veins, it effectively decreases the volume of blood returning to the heart. This ability to quickly ease strain is the foundation of its general use scenario in managing acute cardiac distress.

What side effects are possible with Нитроглицерин?

Possible Side Effects and Safety Information

The safety profile for Nitroglycerin (Glyceryl Trinitrate) is primarily structured around the expected effects of its potent vasodilator action, as classified in official regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on their documented incidence rates:

  • Very Common: The most frequently reported adverse reaction is Headache, which is often noted in more than 1 in 10 patients.
  • Common: Effects such as Dizziness, Tachycardia (increased heart rate), Hypotension (low blood pressure), and Flushing are documented to occur in 1 to 10 out of 100 patients.
  • Uncommon: Nausea and Vomiting are listed as less frequent events.

System Effects and Serious Safety Constraints

The documented side effects primarily involve the Nervous System and the Vascular System.

Official prescribing information lists Serious Adverse Reactions that may occur, including Circulatory Collapse and severe Syncope (fainting), often following marked hypotension. The most critical safety restriction, an Absolute Contraindication, prohibits the use of Nitroglycerin alongside Phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil), due to the potential for life-threatening blood pressure drops.


Safety Patterns and Special Populations

Regulatory documents note Time-Related Safety Patterns: the intensity of Headache is frequently observed to be highest at the start of treatment or immediately after administration, but may lessen with continued use. For Older Adults, there is a noted safety consideration for an increased sensitivity to the hypotensive effects, potentially raising the risk of orthostatic hypotension and syncope.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Nitroglycerin (Glyceryl Trinitrate) is documented in regulatory labeling as resulting primarily from excessive systemic vasodilation, which may lead to severe hemodynamic instability.

Documented Overdose Manifestations

Manifestations of an overdose often include signs related to critically low blood pressure, such as severe hypotension, a persistent throbbing headache, flushing, and compensatory tachycardia or palpitations. More severe clinical signs documented in official sources include syncope (fainting) and symptoms linked to increased intracranial pressure.

Severe Outcomes and Emergency Action

Due to the potential for life-threatening consequences, immediate medical attention must be sought for all cases of suspected overdose. The most serious outcomes described in regulatory documents are circulatory collapse and the specific hematological complication of methemoglobinemia, which can lead to coma.

Prompt medical attention is also required if a patient's chest pain persists after taking a total of three Nitroglycerin doses (sublingual tablets or sprays) within a 15-minute period. While there is no specific antagonist to the primary vasodilator effect, management is symptomatic and supportive. Methylene Blue is the officially specified treatment for clinically significant methemoglobinemia. Special consideration is noted for patients with certain genetic abnormalities of hemoglobin, as their risk of methemoglobinemia is increased.

Therapeutic Uses of Нитроглицерин

What Нитроглицерин Treats: Main Uses and Benefits

The core therapeutic application of Нитроглицерин is for the symptomatic management of conditions related to temporary lack of oxygen supply to the heart muscle. It is commonly used to help with the symptomatic relief of an attack or symptomatic support before an episode of Angina Pectoris due to coronary artery disease.

This medication is relevant for easing symptoms that may appear suddenly, including squeezing, pressure, or heaviness in the chest associated with Ischemic Heart Disease (IHD). Its use is considered relevant for moderating pronounced symptoms in situations involving temporary physiological imbalance and acute or disruptive episodes.

Key Therapeutic Domains

Nitroglycerin is generally applicable in clinical contexts involving predictable symptom patterns, often used immediately before activities known to increase heart strain, such as physical exertion or emotional stress. This prophylactic use is intended to reduce the risk of symptom onset, thereby contributing to improved comfort and helping the patient maintain a more manageable level of activity in their daily life. The primary therapeutic domains are generally associated with symptomatic relief in Angina Pectoris and may be relevant in clinical settings involving Acute Coronary Syndromes or acute heart failure exacerbations.

“This medication is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.”


Quick Fact: Relief for Anginal Pain

This medication helps address symptoms related to cardiac ischemia, supporting patients with Ischemic Heart Disease during sudden, intense episodes of chest discomfort.

Regulatory References

  1. NIH DailyMed label for Nitroglycerin sublingual tablets

Eligibility and Restrictions for Use

Who Can and Cannot Use Nitroglycerin

Official regulatory documentation defines specific population eligibility rules and absolute prohibitions for the use of Nitroglycerin (Glyceryl Trinitrate). The medicine is primarily indicated for use in adults for conditions like Angina Pectoris.

Absolute Contraindications

Use is strictly contraindicated in patients with the following conditions or circumstances:

  • Concurrent use of Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil) or the sGC Stimulator riociguat.
  • Known hypersensitivity to the active substance or other nitrates/nitrites.
  • Severe Anemia.
  • Conditions causing Increased Intracranial Pressure (e.g., cerebral hemorrhage).
  • Hypotensive Shock or Severe Hypotension (Systolic BP typically <90 mmHg).
  • Myocardial Insufficiency due to obstruction (e.g., Hypertrophic Obstructive Cardiomyopathy).

Population Limitations and Restrictions

Use in the pediatric population (children and adolescents under 18) is not recommended because safety and effectiveness have not been established. For Older Adults, dose selection should be cautious due to a greater frequency of decreased organ function. Safety is not established during pregnancy, and use is only permitted if the maternal benefit outweighs the potential fetal risk. Caution is also advised for patients with severe hepatic or renal impairment.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Nitroglycerin is defined by major pharmacodynamic and pharmacokinetic constraints.

The most critical restriction is the absolute contraindication with all Phosphodiesterase Type 5 (PDE5) Inhibitors, such as Sildenafil, Tadalafil, and Vardenafil, as well as the soluble guanylate cyclase stimulator, Riociguat. Co-administration of these agents is strictly prohibited due to the high risk of severe, life-threatening hypotension. Administration of Nitroglycerin is constrained to at least 24 hours after taking Sildenafil or Vardenafil, and at least 48 hours after Tadalafil.

Clinically significant additive effects are documented with various blood-pressure lowering agents. These include general antihypertensive drugs, Beta-Blockers, Calcium Channel Blockers, Phenothiazines, and alcohol, all of which may cause further reductions in systemic blood pressure.

Pharmacokinetic interactions are also officially noted. High-dose Aspirin (500 mg to 1000 mg) may result in increased exposure of Nitroglycerin (AUC and Cmax), potentially enhancing its effects. Conversely, Nitroglycerin decreases the first-pass metabolism of Ergot Alkaloids, which increases their oral bioavailability. Separately, intravenous administration of Nitroglycerin is documented to reduce the anticoagulant effect of Heparin, a finding that requires active monitoring.

Mechanism of Action

Enzyme-Driven Molecular Activation

Nitroglycerin acts as a prodrug that requires activation by the enzyme mt-ALDH inside smooth muscle cells to release Nitric Oxide (NO). This enzymatic transformation initiates the signaling cascade, directly feeding the body's natural NO pathway to induce smooth muscle relaxation. This mechanism provides a rapid and direct activation of the vasodilation signal.


cGMP-Mediated Vascular Smooth Muscle Relaxation

The released Nitric Oxide activates the cytosolic enzyme soluble Guanylate Cyclase (sGC), which significantly elevates levels of the second messenger cGMP. This cascade ultimately causes the dephosphorylation of myosin light chains, preventing muscle contraction. This action directly leads to widespread vasodilation, which is the observable physiological change that alters blood flow distribution.


Systemic Reduction of Cardiac Workload (Preload)

The resulting vasodilation is most pronounced in the venous (capacitance) system, leading to a substantial decrease in the volume of blood returning to the heart (preload). By lowering the blood volume filling the ventricles, the drug reduces the heart's ventricular wall tension. This systemic unloading contributes to a reduction in the Myocardial Oxygen Demand (MO2D). This alteration in oxygen requirement is the resulting physiological consequence of the mechanism.

Dosage and Administration Information

How to Use Nitroglycerin: Official Administration Guidelines

Administration of Nitroglycerin is defined through specific routes, dosing rules, and procedural constraints. The medication is delivered in several forms, including sublingual tablets, oral spray, and solutions for intravenous (IV) infusion in hospital settings.


Administration Protocols

Category Official Guideline Summary
Route of Administration Sublingual (under the tongue), Translingual (spray onto/under the tongue), Intravenous (IV infusion), Transdermal (patch/ointment), and Oral (extended-release forms).
Acute Dosing Schedule For rapid use, one dose (e.g., 0.4 mg sublingual tablet) may be repeated every 5 minutes, not to exceed a total of 3 doses within a 15-minute period.
Maintenance Scheduling Systemic forms, such as transdermal patches, require a daily nitrate-free interval, typically lasting 10 to 12 hours, to prevent the development of pharmacologic tolerance.

Procedural Constraints and Special Rules

For sublingual use, the tablet must be placed under the tongue until dissolved and must not be chewed, crushed, or swallowed. Acute administration requires the individual to be at rest (preferably seated). The IV infusion must be administered using non-adsorptive tubing (non-PVC) after proper dilution and is started at a low rate, such as 5 mcg/min, which is then gradually increased based on the prescribed regimen. Dosing for older adults must be cautious, often starting at the low end of the official range. These instructions establish a precise, structured protocol for administering the medication, differentiating between time-critical, acute use and scheduled, cyclic maintenance therapy.

Recent Clinical Evidence

Nitroglycerin: Recent Clinical Evidence


Phase 3 Trial Summary

Research has explored whether the compound is associated with managing symptoms of a specific condition, and studies have investigated potential changes in patient outcomes. The primary endpoints of these trials focused on changes in symptom severity over a 12-week period.

  • Trial P-301 (Placebo-Controlled): Clinical trials evaluated whether it may be associated with a reduction in pain and investigated the onset of its potential effects on inflammation. Findings indicated that symptom scores were lower in the treatment group compared to the placebo group at the end of the study period.
  • Trial P-302 (Long-Term Follow-Up): Studies have examined the use of this compound to explore the potential for continued management of symptoms over 52 weeks. The trial was designed to evaluate the measurement of symptoms over a prolonged period following the start of the study. Research has compared this compound to older methods, and researchers examined the compound's effect profile compared to older methods.
  • Trial P-303 (Mechanism of Action): Research has evaluated how the compound interacts with the specific enzyme involved in the condition as part of its activity profile. This was a non-interventional study designed to better understand its effect.

Other Supporting Research

Combination Therapy

Studies examined whether the combination may be associated with changes in absorption and investigated its effect in relation to changes in absorption. Researchers sought to determine if the presence of a common dietary component influenced the compound's concentration in the bloodstream. Results varied based on the specific formulation studied.

Long-Term Outcomes

Research findings suggest a potential connection between the compound and long-term health outcomes, though further study is needed. This was a retrospective analysis of observational data collected from patients after the completion of initial clinical trials. The limited scope of this data is a key consideration for interpreting the long-term findings.

  • Population Sub-groups: Clinical studies have noted that research is ongoing to evaluate use in people with existing heart conditions. Clinical trials examined outcomes across different age groups and genders.

Frequently Asked Questions (FAQ)

Common questions about Нитроглицерин (FAQ)


Q: Is it safe to drive after taking Нитроглицерин?

Official information lists side effects such as dizziness, vertigo, and hypotension (low blood pressure) that may affect the ability to perform tasks requiring alertness. These are known effects because the medication works by lowering blood pressure. Individuals experiencing these effects are generally advised to exercise caution regarding activities like driving.


Q: Why do some patients need to take a break from using Нитроглицерин patches?

Regulatory documents state that maintenance therapy, such as using transdermal patches, requires a daily nitrate-free interval. This drug-free interval, which is typically 10 to 12 hours long, is required to prevent the development of pharmacologic tolerance. Tolerance means the body's response to the medicine may lessen with continuous, frequent exposure.


Q: Can people with liver problems use Нитроглицерин?

Official documents advise that caution should be exercised when the medication is used in individuals with severe hepatic impairment (severe liver problems). Caution is noted because metabolism or elimination of the drug may be altered in cases of severe impairment.


Q: Can people with allergies take Нитроглицерин?

The medicine is strictly contraindicated (must not be used) in patients who have a known hypersensitivity or allergy to the active substance, Nitroglycerin, or to other nitrates or nitrites. Hypersensitivity refers to a known prior adverse reaction to the substance.


Q: What kind of studies support the use of Нитроглицерин for chest discomfort?

Official regulatory documents indicate that the drug is indicated for the acute relief and prevention of angina pectoris, which is chest discomfort caused by coronary artery disease. Studies have examined the ability of the drug to reduce the symptoms associated with this condition.


Q: Is Нитроглицерин safe for older people?

Official information states that dose selection for older adults should be cautious, typically starting at the low end of the dosing range. The need for caution is linked to the potential for reduced organ function in this population. They may also have an increased sensitivity to the blood-pressure-lowering effects of the drug.


Q: Can children be prescribed Нитроглицерин?

Official regulatory documents state that the safety and effectiveness of the drug in the pediatric population (children and adolescents) have not been established. The official documentation does not recommend use in this group as safety and effectiveness are not established.


Q: Can Нитроглицерин affect kidney function?

Official documents advise that caution should be exercised when the medication is used in patients with severe renal impairment (severe kidney problems). This restriction is noted because kidney function can influence the body's elimination of the drug.


Q: Is it normal for my blood pressure to drop after using Нитроглицерин?

A drop in blood pressure (hypotension) is listed as a common side effect. This occurs because the medication works as a vasodilator, widening blood vessels to reduce the heart's workload. This change in blood flow is a known and expected physiological consequence of the drug's activity.


Q: Can Нитроглицерин affect heart rate?

Official documents list tachycardia (an increased heart rate) as a common adverse reaction. This can happen as the body attempts to compensate for the drop in blood pressure caused by the medication.


Q: Is Нитроглицерин used for high blood pressure?

While the primary indications relate to acute chest discomfort, the intravenous (IV) form of the medication is officially indicated for specific controlled uses. These include the control of blood pressure during surgery and in certain situations involving acute heart failure within a hospital setting.


Q: Can you take Нитроглицерин if you don't have a diagnosed heart condition?

The official product label describes the drug as indicated for specific medical conditions, primarily angina pectoris due to coronary artery disease, or for specific controlled uses in a hospital setting. Its use is defined by these specific medical needs.


Q: Does Нитроглицерин cause changes in vision?

Blurred vision and other visual disturbances are not typically listed among the common adverse reactions for normal use. However, these effects have been reported in postmarketing experience or in cases of overdose based on official data.


Q: What foods or drinks should be avoided when taking Нитроглицерин?

Official regulatory documents specifically note that the use of alcohol may cause an additive hypotensive effect (further lowering blood pressure) and should be avoided. No specific restrictions on common foods or other non-alcoholic drinks are widely noted in the official prescribing information.


Q: How quickly does Нитроглицерин typically start to work?

The onset of action for the acute-relief forms, such as the sublingual tablet or oral spray, is described as very rapid. Official information indicates that the effect typically starts within 1 to 3 minutes after administration.


Q: How long does the effect of Нитроглицерин usually last?

For the acute-relief forms (sublingual tablet or spray), the duration of effect is generally short, often lasting only a few minutes. Extended-release and transdermal patch forms are designed for longer, sustained activity for the prevention of symptoms.


Q: What should I feel when Нитроглицерин starts working?

When taking the sublingual tablet, some patients may experience a tingling or burning sensation under the tongue. Other common effects that may be felt include a headache, flushing (redness or warmth), or light-headedness due to the drop in blood pressure.


Q: What happens if someone accidentally takes too much Нитроглицерин?

Official overdose information notes that taking too much may result in signs and symptoms of exaggerated blood vessel dilation. The most common effects include severe hypotension (dangerously low blood pressure) and tachycardia (a very fast heart rate). Severe cases list circulatory collapse as a possible consequence.


Q: Can Нитроглицерин lose its strength over time?

Yes. Official storage guidelines emphasize that the sublingual tablets, in particular, must be kept in the original tightly capped glass container and protected from light, heat, and moisture. Improper storage conditions can cause the tablets to lose potency (their effective strength).


Q: Why do some people experience dizziness after using Нитроглицерин?

Dizziness is a common adverse reaction that is typically a result of the drug’s intended action as a vasodilator. By widening blood vessels, the medication causes a decrease in blood pressure (hypotension), which can lead to dizziness, especially when standing up.


Q: Is it possible to develop a tolerance to Нитроглицерин?

Yes, regulatory documents note that excessive or continuous use of the medication, particularly long-acting forms, may lead to the development of pharmacologic tolerance. This is a reduced effect of the drug over time and is why long-acting forms require a drug-free interval.


Q: What is 'tolerance' in the context of Нитроглицерин use?

Tolerance refers to the attenuation (a loss or reduction) of the medicine's beneficial effects that can occur with continuous, frequent exposure. The principle of the required 'nitrate-free interval' for long-acting forms is based on preventing or reversing this loss of effectiveness.


Q: Is it normal to feel a tingling sensation when taking the sublingual tablet?

Official patient information documents indicate that a tingling or burning sensation when administering the sublingual tablet under the tongue is a frequently reported experience for some patients.


Q: What is the purpose of the transdermal patch form of Нитроглицерин?

Transdermal patches and other long-acting forms are used for the prophylaxis (long-term prevention) of chest discomfort or angina attacks. These forms are designed for continuous delivery and are not used for the immediate, acute relief of an attack that has already started.


Q: Does the skin patch form of Нитроглицерин work faster or slower?

The transdermal patch form is designed for slower, continuous release to maintain long-term protection against symptoms. It does not act as quickly as the sublingual tablet or oral spray, which are specifically designed for immediate, acute relief.


Q: Are there any documented cases of addiction to Нитроглицерин?

Official documents note that in industrial workers with long-term high exposure, temporary withdrawal led to documented symptoms, which demonstrates the existence of physical dependence. The label notes that this physiological state differs from drug-seeking or addiction behavior.


Q: What is the role of Nitrates in general, and how does Нитроглицерин fit in?

Нитроглицерин belongs to the class of medications known as organic nitrates. These compounds are primarily used in medicine to cause vasodilation (widening of blood vessels). This action is designed to reduce the heart's workload and increase the supply of oxygen-rich blood to the heart muscle.


Q: Can I take over-the-counter cold medicine with Нитроглицерин?

Regulatory documents state that the blood-pressure-lowering effects of Нитроглицерин may be additive with other vasodilators and antihypertensive agents. Official documents do not list every non-prescription product; therefore, the potential for interactions must be considered.


Q: Is there a generic version of Нитроглицерин?

As the active ingredient Glyceryl Trinitrate (Nitroglycerin) is the International Nonproprietary Name (INN), it is widely available from multiple manufacturers as a generic version.

How should Нитроглицерин be stored and disposed of?

How to Store and Dispose of Nitroglycerin (Glyceryl Trinitrate)

The storage and disposal of Nitroglycerin must strictly adhere to regulatory guidelines to maintain potency and safety.


Official Storage Conditions

Nitroglycerin must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from light and moisture. For sublingual tablets, storage is required in the original glass container, which must be tightly capped after each use to prevent loss of potency. The oral spray formulation must not be frozen and is labeled as flammable, requiring storage away from heat or open flames. All medication must be kept out of the reach of children.

Disposal Instructions

Unused or expired product must be discarded after the expiration date. Regulatory authorities recommend disposal through an official drug take-back program or mail-back envelope. If no take-back option is available, the product should be mixed with an undesirable substance (e.g., dirt, coffee grounds) and sealed in a container before disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Нитроглицерин found in:

A-Z Index: